Guardant Health, Inc. (GH): Cost of Revenue

Annual figures by period end, from SEC filings.

$349.01M

Year ended 2025-12-31

$413.95M

Trailing 12 months to 2026-06-30

2023-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$349.01M	+20.4%	2026-02-19, From 2025-01-01
2024-12-31	$289.80M	+27.6%	2026-02-19, From 2024-01-01
2023-12-31	$227.05M	n/a	2026-02-19, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Guardant Health, Inc. (GH)	2025-12-31	$349.01M	+20.4%
Castle Biosciences Inc (CSTL)	2025-12-31	$71.03M	+18.0%
Fulgent Genetics, Inc. (FLGT)	2025-12-31	$191.80M	+8.8%
BillionToOne, Inc. (BLLN)	2025-12-31	$96.65M	+34.9%
Quest Diagnostics Inc (DGX)	2025-12-31	$7.37B	+11.2%
Personalis, Inc. (PSNL)	2025-12-31	$53.87M	-6.8%
Labcorp Holdings Inc. (LH)	2025-12-31	$9.94B	+5.9%
Exagen Inc. (XGN)	2025-12-31	$27.78M	+23.3%
American Shared Hospital Services (AMS)	2025-12-31	$23.02M	+20.2%

Compare GH, CSTL, FLGT, BLLN side by side · Screen every company in Services-Medical Laboratories ↗